{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:19:38Z","timestamp":1788239978153,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118392","type":"journal-article","created":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:22:33Z","timestamp":1787494953000},"page":"118392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["DNMT1 is associated with anti-PD-1 resistance and regulates the STAT3\/PD-L1\u2013CD8+ T-cell axis in melanoma"],"prefix":"10.1016","volume":"254","author":[{"given":"Yujia","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanxin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bcp.2026.118392_b0005","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.bcp.2026.118392_b0010","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","author":"Ferlay","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2026.118392_b0015","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ejca.2021.07.039","article-title":"The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers","volume":"157","author":"Dyba","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bcp.2026.118392_b0020","doi-asserted-by":"crossref","unstructured":"Jitian Mihulecea CR, Rotaru M. Review: The Key Factors to Melanomagenesis. Life (Basel). 2023;13(1).","DOI":"10.3390\/life13010181"},{"issue":"2","key":"10.1016\/j.bcp.2026.118392_b0025","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020409","article-title":"Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: a Propensity-Matched Outcome Analysis","volume":"15","author":"De Meza","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"10304","key":"10.1016\/j.bcp.2026.118392_b0030","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bcp.2026.118392_b0035","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","article-title":"A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance","volume":"23","author":"Huang","year":"2022","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118392_b0040","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.hoc.2020.08.013","article-title":"Immune Checkpoint Therapies for Melanoma","volume":"35","author":"Buchbinder","year":"2021","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"17","key":"10.1016\/j.bcp.2026.118392_b0045","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1016\/j.cell.2021.07.015","article-title":"CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment","volume":"184","author":"Di Pilato","year":"2021","journal-title":"Cell"},{"issue":"7953","key":"10.1016\/j.bcp.2026.118392_b0050","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41586-023-05787-1","article-title":"Neoantigen-targeted CD8+ T cells mediate antitumor efficacy of adoptive cell therapy","volume":"615","author":"Puig-Saus","year":"2023","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bcp.2026.118392_b0055","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.molcel.2021.01.010","article-title":"Interferon-gamma induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation","volume":"81","author":"Yu","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2026.118392_b0060","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.canlet.2020.02.036","article-title":"IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma","volume":"477","author":"Li","year":"2020","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.bcp.2026.118392_b0065","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.bcp.2026.118392_b0070","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000807","article-title":"Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma","volume":"8","author":"He","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2026.118392_b0075","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118392_b0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2017.07.022","article-title":"Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma","volume":"86","author":"Hamid","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"18","key":"10.1016\/j.bcp.2026.118392_b0085","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1002\/cam4.4190","article-title":"PD-1\/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies","volume":"10","author":"Ding","year":"2021","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118392_b0090","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s12967-023-04200-9","article-title":"The role of mitochondria in the resistance of melanoma to PD-1 inhibitors","volume":"21","author":"Du","year":"2023","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118392_b0095","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2026.118392_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.874589","article-title":"Tumor-Associated Macrophages Regulate PD-1\/PD-L1 Immunosuppression","volume":"13","author":"Pu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118392_b0105","article-title":"PD-1\/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118392_b0110","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations Associated with acquired Resistance to PD-1 Blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118392_b0115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13148-025-01865-5","article-title":"DNA methylation in melanoma immunotherapy: mechanisms and therapeutic opportunities","volume":"17","author":"Deshmukh","year":"2025","journal-title":"Clin. Epigenetics"},{"issue":"1","key":"10.1016\/j.bcp.2026.118392_b0120","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13148-022-01270-2","article-title":"DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy","volume":"14","author":"Niebel","year":"2022","journal-title":"Clin. Epigenetics"},{"issue":"7","key":"10.1016\/j.bcp.2026.118392_b0125","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002226","article-title":"DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma","volume":"9","author":"Filipski","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2026.118392_b0130","doi-asserted-by":"crossref","first-page":"5595","DOI":"10.2147\/JIR.S377678","article-title":"The DPY30-H3K4me3 Axis-Mediated PD-L1 Expression in Melanoma","volume":"15","author":"Zhang","year":"2022","journal-title":"J. Inflamm. Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.118392_b0135","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2024.01.008","article-title":"SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion","volume":"187","author":"Leuzzi","year":"2024","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bcp.2026.118392_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061697","article-title":"T Cell Immunoglobulin and Mucin Domain 3 (TIM-3) in Cutaneous Melanoma: a Narrative Review","volume":"15","author":"Cazzato","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2026.118392_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155468","article-title":"Expression of immune checkpoint molecules TIGIT and TIM-3 by tumor-infiltrating lymphocytes predicts poor outcome in sinonasal mucosal melanoma","volume":"260","author":"Ledderose","year":"2024","journal-title":"Pathol. Res. Pract."},{"issue":"5","key":"10.1016\/j.bcp.2026.118392_b0150","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/CMR.0000000000000818","article-title":"Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III\/IV melanoma","volume":"32","author":"Weber","year":"2022","journal-title":"Melanoma Res."},{"issue":"9","key":"10.1016\/j.bcp.2026.118392_b0155","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","article-title":"Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial","volume":"29","author":"VanderWalde","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.118392_b0160","article-title":"GSK-3484862 targets DNMT1 for degradation in cells. NAR","volume":"5(2):zcad022","author":"Chen","year":"2023","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118392_b0165","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13046-024-03063-2","article-title":"Targeting DNMT1-dependent IGFBP2\/EGFR\/STAT3\/PD-L1 pathway improves the efficacy of immunotherapy in prostate cancer","volume":"43","author":"Xu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118392_b0170","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1989790","article-title":"DNMT1 constrains IFNbeta-mediated anti-tumor immunity and PD-L1 expression to reduce the efficacy of radiotherapy and immunotherapy","volume":"10","author":"Huang","year":"2021","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.bcp.2026.118392_b0175","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood-2018-01-829424","article-title":"Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer\/T-cell lymphoma","volume":"132","author":"Song","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcp.2026.118392_b0180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031119","article-title":"Epigenetic Modification of PD-1\/PD-L1-Mediated Cancer Immunotherapy against Melanoma","volume":"23","author":"Nanamori","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118392_b0185","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.isci.2018.05.021","article-title":"Marked Global DNA Hypomethylation is Associated with Constitutive PD-L1 Expression in Melanoma","volume":"4","author":"Chatterjee","year":"2018","journal-title":"iScience"},{"issue":"5","key":"10.1016\/j.bcp.2026.118392_b0190","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1158\/2767-9764.CRC-23-0406","article-title":"Comparative Epigenetic Profiling reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and their Clinical Implications","volume":"4","author":"Dai","year":"2024","journal-title":"Cancer Res. Commun."},{"issue":"7","key":"10.1016\/j.bcp.2026.118392_b0195","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1002\/cam4.3649","article-title":"Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer","volume":"10","author":"Shi","year":"2021","journal-title":"Cancer Med."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226007318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226007318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:04:04Z","timestamp":1788239044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226007318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":39,"alternative-id":["S0006295226007318"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118392","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNMT1 is associated with anti-PD-1 resistance and regulates the STAT3\/PD-L1\u2013CD8+ T-cell axis in melanoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118392","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118392"}}